Biocon Biologics gains market access coverage for Yesintek in the US
Yesintek is a biosimilar to Stelara (ustekinumab) and is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
STELARA
Biocon Biologics gets US market entry date for Bmab 1200, a proposed biosimilar to Stelara
Stelara (Ustekinumab) has been approved for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and…
Crohn’s disease treatment market sees major shift with biosimilars and next-gen therapies:…
The recent launch of adalimumab biosimilars not only will cause an overall reduction in the cost of treatment, but also provide…
Janssen presents five year data of STELARA in treatment of Crohn’s Disease
Over half of the patients with moderately to severely active CD who were randomised to subcutaneous ustekinumab every eight weeks…